Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
$588M |
| 2 |
Apple
AAPL
|
$574M |
| 3 |
Illumina
ILMN
|
$398M |
| 4 |
Monster Beverage
MNST
|
$396M |
| 5 |
argenx
ARGX
|
$306M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$600M |
| 2 |
AbbVie
ABBV
|
$323M |
| 3 |
Sherwin-Williams
SHW
|
$309M |
| 4 |
Atlassian
TEAM
|
$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Nurix Therapeutics
NRIX
$696M
| $115K | ﹤0.01% |
+12,954
| New | +$115K |
|
2602
Scholar Rock
SRRK
$3.18B
| $115K | ﹤0.01% |
+14,286
| New | +$115K |
|
2603
MiMedx Group
MDXG
$1.06B
| $114K | ﹤0.01% |
33,649
+18,874
| +128% | +$64.1K |
|
2604
Unisys
UIS
$272M
| $113K | ﹤0.01% |
29,089
+16,266
| +127% | +$63K |
|
|
SRG
2605
Seritage Growth Properties
SRG
$210M
| $113K | ﹤0.01% |
+14,308
| New | +$113K |
|
2606
Tredegar Corp
TG
$263M
| $111K | ﹤0.01% |
+12,163
| New | +$111K |
|
2607
ATAI Life Sciences
ATAI
$984M
| $110K | ﹤0.01% |
61,508
+29,569
| +93% | +$53.1K |
|
2608
ImmunityBio
IBRX
$2.25B
| $109K | ﹤0.01% |
60,325
+28,703
| +91% | +$52.1K |
|
2609
Radiant Logistics
RLGT
$301M
| $109K | ﹤0.01% |
16,565
-1,662
| -9% | -$10.9K |
|
2610
Codexis
CDXS
$227M
| $105K | ﹤0.01% |
25,507
+13,703
| +116% | +$56.5K |
|
2611
Altimmune
ALT
$331M
| $101K | ﹤0.01% |
23,986
-3,809,593
| -99% | -$16.1M |
|
2612
Sangamo Therapeutics
SGMO
$163M
| $99.7K | ﹤0.01% |
56,831
+32,100
| +130% | +$56.3K |
|
|
PSTX
2613
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $99.7K | ﹤0.01% |
+32,317
| New | +$99.7K |
|
2614
Sana Biotechnology
SANA
$721M
| $98.8K | ﹤0.01% |
30,247
+20,172
| +200% | +$65.9K |
|
2615
Clarus
CLAR
$134M
| $96.6K | ﹤0.01% |
+10,231
| New | +$96.6K |
|
2616
Atara Biotherapeutics
ATRA
$86.7M
| $95K | ﹤0.01% |
32,828
+18,269
| +125% | +$52.9K |
|
2617
Hyliion Holdings
HYLN
$282M
| $94.7K | ﹤0.01% |
47,956
+28,736
| +150% | +$56.8K |
|
2618
fuboTV
FUBO
$1.29B
| $93.1K | ﹤0.01% |
77,240
+41,058
| +113% | +$49.5K |
|
2619
Vuzix
VUZI
$166M
| $92.9K | ﹤0.01% |
+22,578
| New | +$92.9K |
|
|
TVRD
2620
Tvardi Therapeutics, Inc. Common Stock
TVRD
$277M
| $92.8K | ﹤0.01% |
+18,924
| New | +$92.8K |
|
2621
BrightView Holdings
BV
$1.36B
| $92K | ﹤0.01% |
+16,391
| New | +$92K |
|
2622
Butterfly Network
BFLY
$388M
| $91.5K | ﹤0.01% |
48,543
+28,268
| +139% | +$53.3K |
|
2623
Ranpak Holdings
PACK
$420M
| $87.3K | ﹤0.01% |
+16,758
| New | +$87.3K |
|
2624
Kodiak Sciences
KOD
$455M
| $87.2K | ﹤0.01% |
+14,037
| New | +$87.2K |
|
2625
Workhorse Group
WKHS
$19.8M
| $84.8K | ﹤0.01% |
63,995
+41,671
| +187% | +$55.2K |
|